Search
Podofilox
go.drugbank.com/drugs/DB01179ApprovedA lignan found in podophyllin resin from the roots of podophyllum plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic.
Meticillin
go.drugbank.com/drugs/DB01603ApprovedInvestigationalOne of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.
CYNK-001
go.drugbank.com/drugs/DB15722InvestigationalCYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
Cobolimab
go.drugbank.com/drugs/DB16372InvestigationalCobolimab is under investigation in clinical trial NCT04655976 (Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants).
Rulonilimab
go.drugbank.com/drugs/DB18922InvestigationalRulonilimab is under investigation in clinical trial NCT05408221 (The Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma).
Fallypride
go.drugbank.com/drugs/DB15167InvestigationalFallypride is under investigation in clinical trial NCT02310360 (Striatal and Extra-striatal Dopamine Release in Response to Food in Healthy Humans).
Trigonellamide
go.drugbank.com/drugs/DB11710InvestigationalTrigonellamide is under investigation in clinical trial NCT01930240 (The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers).
AZD-5991
go.drugbank.com/drugs/DB14792InvestigationalAZD-5991 is under investigation in clinical trial NCT03218683 (Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.).
RO-5045337
go.drugbank.com/drugs/DB14793InvestigationalRO-5045337 is under investigation in clinical trial NCT01164033 (A Study of RO5045337 in Patients With Solid Tumors).
Tibulizumab
go.drugbank.com/drugs/DB14848InvestigationalTibulizumab is under investigation in clinical trial NCT03736772 (A Study of LY3090106 in Japanese and Caucasian Healthy Participants).